Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.gastro.2022.06.025 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in vivo.
Transl Oncol
August 2025
Department of Protein Science, AlbaNova University Center, KTH Royal Institute of Technology, SE-144 21 Stockholm, Sweden; Science for Life Laboratories, Karolinska Institute, SE-171 65 Solna, Sweden. Electronic address:
We report development and characterization of small non-immunoglobulin affibody affinity proteins directed to the highly glycosylated human carcinoembryonic antigen-related adhesion molecule 5 (CEACAM5, CEA), and their use in immunohistochemical (IHC) analyses of human pancreatic cancer samples and for in vivo tumor imaging. A total of nineteen unique anti-CEA affibodies were identified from large phage display libraries constructed using combinatorial protein engineering of a small 58 amino acid three-helix bundle protein domain. Molecular modeling suggested that all enriched clones share a binding surface with several clustered tryptophan residues interacting with a hydrophobic patch in the N1 domain of CEA centered around a phenylalanine residue.
View Article and Find Full Text PDFAdvancing precision antibody-drug conjugate therapy: unique proteogenomic profiles of tumor subsets in non-small cell lung cancer.
Exp Hematol Oncol
July 2025
University of Alabama Birmingham, 1802 6th Ave South, Birmingham, AL, 35294, USA.
Antibody-drug conjugates (ADCs) represent a promising therapeutic strategy for non-small cell lung cancer (NSCLC), targeting tumor-specific antigens with precision. However, the molecular heterogeneity of NSCLC necessitates multiplex biomarker approaches to optimize ADC efficacy. This study utilized transcriptomics and proteomics to characterize NSCLC subtypes with distinct ADC target expression profiles.
View Article and Find Full Text PDFPlasma proteomic profiles for early detection and risk stratification of non-small cell lung carcinoma: A prospective cohort study with 52,913 participants.
Int J Cancer
October 2025
State Key Laboratory of Genetics and Development of Complex Phenotypes, Human Phenome Institute, Zhangjiang Fudan International Innovation Center, Fudan University, Shanghai, China.
Early detection of non-small cell lung cancer (NSCLC) can improve survival rates, and plasma proteomics may provide effective tools for risk prediction. The population for this study included 52,913 participants and 2911 plasma proteomics from UK Biobank. The cohort was divided into discovery and validation cohorts based on their countries.
View Article and Find Full Text PDFIntroduction: Antibody-drug conjugates (ADCs) represent a promising new therapeutic class in non-small-cell lung cancer (NSCLC) patients. Studies assessing ADC have highlighted a pulmonary toxicity profile in the form of interstitial lung disease (ILD).
State Of The Art: Several ADCs for NSCLC are currently being developed.
Molecular Subtype Identification and Potential Drug Prediction Based on Anoikis-Related Genes Expression in Keratoconus.
Invest Ophthalmol Vis Sci
February 2025
Tianjin Eye Hospital, Nankai University Affiliated Eye Hospital, Clinical College of Ophthalmology, Tianjin Medical University, Tianjin Eye Institute, Tianjin Key Laboratory of Ophthalmology and Visual Science, Tianjin, China.
Purpose: Anoikis is a special apoptosis accompanied by the loss of extracellular matrix (ECM) environment and the decomposition of ECM is an important process in the occurrence of keratoconus (KC). This study aims to describe the expression profile of anoikis-related genes (ARGs) in KC samples, identify differentially expressed genes (DEGs), characterize the biological functions and immune characteristics of different molecular subtypes of KC and predict potential drugs based on the construction of a co-expression network.
Methods: First, we identified molecular subtypes by optimal clustering K based on the expression profile of ARGs in the KC dataset and analyzed the differences of functional and immune characteristics.